Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Mayo Clinic has provided personalized or precision medicine to every one of its patients for nearly 150 years. But in recent years, advances in genomic and clinical science have created innovative opportunities to further tailor health care to each patient.
Morgan was diagnosed with short telomere syndrome, caused by inherited gene mutations.
Mallory shares her family's struggle with having abnormally low platelets in the blood.
Larry's pancreatic cancer was linked to an inherited gene mutation.
Genetic testing brings attention to individually rare, but collectively common genetic diseases.
Predictive genetic testing helps the family of a young patient with ulcerative colitis.
Whole-exome sequencing probes into a young patient's bone and joint pain.
RNA sequencing identifies DNA changes that caused genetic abnormalities.
Pharmacogenomic testing provided insight into why certain medications didn't work for Nicole.
Pharmacogenomic testing helps a patient and her family members find answers to health-related questions.
Applied pharmacogenomics resolves a patient's lifelong anxiety and depression.
Microbiome transplant clears a patient's antibiotic-resistant intestinal infection.
Genome sequencing reveals a rare gene mutation.
Sequencing uncovers the genetic makeup of an aggressive tumor.
Whole-genome sequencing provides a diagnosis for a patient with a rare neurological disorder.
Obscure symptoms are mapped to a rare pediatric disorder.
Individualized, precision or personalized medicine provides a genomic blueprint to determine each person's unique disease susceptibility, define preventive measures and enable targeted therapies to promote wellness.
The Biomarker Discovery Program captures genetic information from cells and analyzes it, searching for genetic patterns to help physicians make more precise diagnoses and prescribe more effective, individualized treatments.
The Microbiome Program explores the genetic code of the body's microorganisms, using the latest techniques to profile an individual's microbiome to detect, prevent and diagnose infections and other diseases.
The Pharmacogenomics Program investigates how variations in genes affect response to medications, thereby using a patient's genetic profile to predict a drug's efficacy, guide dosage and improve patient safety.
Genomic sequencing is a process for analyzing a sample of DNA taken from your blood. In the lab, technicians extract DNA and prepare it for sequencing.
The Clinomics Program quickly moves discoveries from the research lab to the clinical setting, with practical, cost-efficient genomic tests for diagnosing and treating patients.
The Epigenomics Program investigates the role of the epigenome, examines which factors act on individual genes, and how certain changes in the epigenome affect our health.
Better diagnoses, earlier interventions, more-efficient drug therapies, customized treatment plans — these are the promises of personalized medicine, also known as precision medicine or individualized medicine.
Living better, living longer
Imad Absah, M.D. — Collaboration with Pharmacists
Imad Absah, M.D. — Implementing Pediatric Practice
Imad Absah, M.D. — Importance of PGx to Patient Care
Imad Absah, M.D. Patient Case — Crohn's, Acid Reflux & Anxiety
Imad Absah, M.D. Patient Case — Esophagitis, Ulcers & Acid Reflux
Imad Absah, M.D. — When to Use PGx Testing
Stephanie L. Hines, M.D. — Advice for Colleague
Stephanie L. Hines, M.D. — Personal Testing
Konstantinos N Lazaridis, M.D. Provider Stories — Pharmacogenomics
Michael C. Stephens, M.D. — Concerns of PGx Testing
Michael C. Stephens, M.D. — New Clinical Tool for Patient Care
Michael C. Stephens, M.D. — Traditional Use of PGx Testing
The Center for Individualized Medicine at Mayo Clinic is taking the practice of personalized medicine and applying it to the entire spectrum of health care using sophisticated methods of genomic sequencing and molecular analysis to drive advances in diagnosis, treatment, prediction and prevention.
George Vasmatzis, Ph.D., co-director, Biomarker Discovery Program
Matthew J. Ferber, Ph.D., and Eric D. Wieben, Ph.D., co-directors, Clinomics Program
Tamas Ordog, M.D., director, Epigenomics Program
Heidi Nelson, M.D., director, Microbiome Program
Richard Weinshilboum, M.D., director, Pharmacogenomics Program
Richard Sharp, Ph.D., director, Bioethics Program
Jean-Pierre A. Kocher, Ph.D., director, Bioinformatics Program
James R. Cerhan, M.D., Ph.D., co-director, Biorepositories Program
James D. Buntrock, director, Information Technology Program
Eric D. Wieben, Ph.D., director, Medical Genome Facility
The Center for Individualized Medicine is a strategic priority for the Campaign for Mayo Clinic.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.